Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Philippines FDA is rationalizing and streamlining its fee structure to help strengthen regulatory enforcement and post-marketing surveillance activities. The effort will include fee increases that are intended to address rising operational costs.
The new fee structure comes as the Department of Health is in the midst of enacting Administrative Order No. 2018-2002, an updated regulatory system that could be implemented in the second or third quarter of 2018. (Also see "Asia Reg Roundup: Philippines Sets Short Reg System Deadline, Vietnam Defers, Malaysia Extends" - Medtech Insight, 16 Feb, 2018.)
The current schedule of fees was implemented in 2001, and the local FDA has not introduced any increase in fees and charges since then. Now, with upgrades in services and the use of electronic registration, a fee increase is necessary to finance the full implementation of the agency’s Five-Year Development Plan, which was launched in 2016 under Director General Nela Charade Puno. The new fees are being implemented by the FDA Center for Device Regulation, Radiation Health and Research.
Under the new system, a standard medical device manufacturer will have to pay a one-time establishment license fee of 75,000 Philippine Pesos (PhP; US$1,400), plus an annual fee. (See Table 1.)
In addition, device-makers will need to pay "application" and "evaluation" fees for product submissions, in addition to an annual fee for products. (See Table 2.) Other fees will be collected for a quality system certificate (PhP 5,000), safety evaluation report (PhP 5,000), and a certificate of radiation measurement for extremely low frequency (ELF) and radiofrequency radiation (RFR) facilities (PhP 14,000).
* Includes devices incorporating medicinal/therapeutic products
The fees and charges for licensing, inspections and certain laboratory service fees will take effect 15 days after publication in two newspapers of general circulation. Fees and charges for product notification and registration will be formally announced separately.
The agency's five-year plan, in its first phase, seeks to improve information system management, move toward digitization and, generally, improve ways of doing business. A second phase will focus on accelerating growth, investing in new technologies, streamlining application processes and overseeing the launch of electronic licenses to operate (e-LTOs). The LTO validity has been extended from three to five years.
Even before the fee increase, progress has been good, FDA says. Achievements so far include the fulfillment of a 72-hour turnaround time for application processing, cutting the application backlog by 91% and strengthening regulatory enforcement. A joint FDA-Philippine National Police task force has been set up to destroy products that are unfit for use in patients.
On the digital front, online payment systems will be expanded, and an FDA mobile app is being developed for online transactions and payments. Philippines FDA is currently migrating its servers and applications to the cloud.
The additional fees will be used by all supporting units of the FDA, according to the device center. The agency says the funds are needed for it to carry out its mandate of regulatory enforcement, improve its in-house lab services and increase manpower.
In Vivo: strategic insights for life sciences decision-maker...
Pharma Intelligence offers a wealth of pharmaceutical industry news and strategic insight into the healthcare & biotechnology markets from around the world. Working in an interconnected global network, our 65 journalists and over 300 in-house analysts supply comprehensive analysis and reports.
Scrip: industry news and insights
The Swiss major's pharma chief tells Scrip that its gene therapy for SMA offers much more than Biogen's Spinraza for both patients and payers, noting that the company is ready with alternative payment models for the pricey treatment as soon as approvals for Zolgensma are granted.
Topics Business strategies Drug approval Drug development landscape Drug review
Scrip: industry news and insights
By Emily Hayes
In second Phase III diabetes study to report, oral GLP-1 agonist semaglutide misses some weight loss goals when compared with Boehringer/Lilly's SGLT-2 inhibitor Jardiance.
Request a Trial
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
Get a window into what the leading players across the biopharma, medtech, and diagnostics industries are thinking, as well as important insight into what your competitors are doing. Build your strategy with In Vivo.
In the continually evolving medtech competitive landscape, it is vital to stay up-to-date with key events. With Meddevicetracker, you’ll be able to anticipate upcoming filings, research clinical trial dates and data, and access market size information and expert forecasts, all in one place.
Looking for more products Product Finder
